Four-Pronged attack on Tough-to-Treat lymphoma
NCT ID NCT05615636
Summary
This study is testing whether a combination of four different immunotherapy and targeted therapy drugs can help control two types of B-cell lymphoma that have returned after prior treatment. It will enroll about 36 adults whose lymphoma has progressed despite at least one previous therapy. The main goals are to see if the drug combination is safe and how well it shrinks tumors in patients with relapsed diffuse large B-cell lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.